Modulating the PI3K Signalling Pathway in Activated PI3K Delta Syndrome: a Clinical Perspective
Open Access
- 27 December 2023
- journal article
- review article
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 44 (1) , 1-10
Abstract
Activated phosphoinositide-3-kinase (PI3K) δ syndrome (APDS) is an inborn error of immunity characterised by immune dysregulation. Since the discovery of genetic mutations resulting in PI3Kδ overactivation, treatment of APDS patients has begun to focus on modulation of the PI3K pathway in addition to supportive therapies. The mTOR inhibitor sirolimus has been used effectively for some clinical manifestations of this condition, however the arrival of specific PI3Kδ inhibitor leniolisib has shown promising early results and may provide a more targeted approach. This review summarizes key aspects of PI3K pathway biology and discusses potential options for nuanced modulation of the PI3K pathway in APDS from a clinical perspective, highlighting differences from PI3K inhibition in haematological malignancies.Keywords
Funding Information
- University of Sydney
This publication has 76 references indexed in Scilit:
- Signaling by the Phosphoinositide 3-Kinase Family in Immune CellsAnnual Review of Immunology, 2013
- mTOR Signaling in Growth Control and DiseaseCell, 2012
- Agammaglobulinemia and absent B lineage cells in a patient lacking the p85α subunit of PI3KJournal of Experimental Medicine, 2012
- Effects of genetic polymorphisms on the pharmacokinetics of calcineurin inhibitorsAmerican Journal of Health-System Pharmacy, 2006
- Chronopharmacokinetics of Ciclosporin and TacrolimusClinical Pharmacokinetics, 2006
- SirolimusClinical Pharmacokinetics, 2005
- Short sirolimus half‐life in pediatric renal transplant recipients on a calcineurin inhibitor‐free protocolPediatric Transplantation, 2004
- A Crucial Role for the p110δ Subunit of Phosphatidylinositol 3-Kinase in B Cell Development and ActivationJournal of Experimental Medicine, 2002
- Impaired B and T Cell Antigen Receptor Signaling in p110δ PI 3-Kinase Mutant MiceScience, 2002
- Identification of a Novel Route of Extraction of Sirolimus in Human Small Intestine: Roles of Metabolism and SecretionThe Journal of Pharmacology and Experimental Therapeutics, 2002